In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now.
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease. Andrew Fein, managing director of equity research at H.C. Wainwright, said that “the worst case scenarios have largely been taken off the table,” noting better clarity following policy moves under Donald Trump. According to Dealogic data, IPO activity fell to 10 listings in 2025, the fewest in over a decade, down from 26 in 2024 and 93 in 2021, with proceeds decreasing to $1.6 billion from $16 billion in 2021.
Sentiment improved as equities gained momentum, with David Wagner claiming pricing trends became “more optimistic” in late 2025. Kevin Eisele, managing director at William Blair, said investors are more willing to deploy capital regardless of “headline risk.” Based on Seth Rubin, head of global equity capital markets at Stifel, markets will not return to their previous highs but will become “much more robust.”
With that said, here are the 8 Most Promising Biotech Stocks to Buy Now.
Vlad Teodor/Shutterstock.com
Methodology:
We used screeners to identify Biotech stocks with an average upside potential of at least 15%, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
On April 30, Oppenheimer raised its price target on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) from $104 to $111. It maintained an “Outperform” rating on the stock while noting shares rose after first-quarter results and updated guidance.
On April 29, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported first-quarter 2026 results. Growing demand for TRYNGOLZA is driven by launch execution while raising full-year revenue guidance.
The company said the FDA accepted the olezarsen sNDA for priority review, with launch preparations for severe hypertriglyceridemia progressing, while growing peak net sales guidance for TRYNGOLZA to over $3 billion.
The pipeline advanced. The firm said the FDA accepted the “zilganersen NDA” for priority review, positioning its first independent neurology launch.
CEO Brett Monia summed it up simply by stating that the business is performing well on both the commercial and R&D fronts. He noted future Phase 3 readouts and launches for olezarsen and zilganersen this year.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a firm that develops and markets human therapeutic drugs using antisense technology. It is based in Carlsbad, California.
7. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
On May 8, Evercore ISI raised its price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $130 from $125. It maintained an “Outperform” rating on the stock.
On May 7, BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted first-quarter 2026 results, showing $194.5 million in total revenue. The revenue comprised of $180.6 million from U.S. Attruby net product sales, fueled by prescribing growth and patient persistence.
The company said demand grew across patient types, pointing out strong uptake among treatment-naive patients. It noted global traction following a Brazil approval.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) said real-world evidence showed Attruby reduced diuretic intensification by 43% versus tafamidis, citing an analysis released on medRxiv and an independent study presented at SCAI.
Pipeline activity continued, with the company stating it submitted an NDA for BBP-418 and plans filings for encaleret and infigratinib in 2026.
The firm reported $940.2 million in cash as of March 31 and authorized a $500 million share repurchase program.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) identifies and promotes novel medications to treat Mendelian diseases. Its development pipeline contains product candidates at various stages of development, from early discovery to late-stage development.
6. Summit Therapeutics Inc. (NASDAQ:SMMT)
On May 4, H.C. Wainwright reduced its price goal on Summit Therapeutics Inc. (NASDAQ:SMMT) to $23 from $30. The firm also noted a weaker interim signal from HARMONi-3 and flagged added risk to the final squamous readout expected in the 2026 second half.
On April 30, Summit Therapeutics Inc. (NASDAQ:SMMT) released its first quarter 2026 results. More than 4000 individuals have received ivonescimab in clinical studies throughout the world. It has been used commercially by over 70000 patients in China through a partner, Akeso.
The business also mentioned that the independent monitoring committee recommended continuing the HARMONi-3 squamous cohort as planned. Final progression-free survival findings are expected in the 2026 second half, and no safety hazards were detected.
Summit Therapeutics Inc. (NASDAQ:SMMT) had $598.7 million in cash on March 31, down from $713.4 million at the end of the year, while GAAP operating costs grew to $195.2 million from $66.8 million.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical firm. The company’s main product, Ridinilazole, is an orally given small molecule antibiotic now in Phase III clinical research to treat CDI.
While we acknowledge the potential of SMMT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SMMT and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Most Promising Biotech Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
